Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FURESTEM-CD in Recessive Dystrophic Epidermolysis Bullosa
NCT04520022Phase 2Completed
- Sponsor
- Gangnam Severance Hospital
- Start
- Oct 2016
- Primary completion
- Jan 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of furestem-cd in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by Gangnam Severance Hospital. Started Oct 2016; status: completed.
02
Drugs
furestem-cd
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT04520022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04520022.